All stock lists
Aktis Oncology, Inc. (NASDAQ:AKTS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
15.83+0.10 (+0.65%)
Insider Score
––Not scored
AKTS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
AKTS Stock Insider Trading Activity
AKTS stock’s insider trading shows 11 sales on the open market for an estimated $3.23M by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days0 qualifying buys0 insiders$0 bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Czibere Akos Other | Option exercise | 12,500 | $4.95 | $61.88K | New | 12,500 | Sep 23, 2026 | — | Form 4 |
| Czibere Akos Other | Sell | 5,099 | $20.19 | $102.97K | 40.8% | 7,401 | Sep 23, 2026 | — | Form 4 |
| Czibere Akos Other | Sell | 7,401 | $21.03 | $155.65K | 100% | 0 | Sep 23, 2026 | — | Form 4 |
| Herrmann Ken Director | Option exercise | 3,506 | $0.08 | $280.48 | New | 3,506 | Jul 20, 2026 | — | Form 4 |
| Herrmann Ken Director | Option exercise | 1,350 | $1.91 | $2.58K | 38.5% | 4,856 | Jul 20, 2026 | — | Form 4 |
| Herrmann Ken Director | Sell | 3,506 | $24.56 | $86.12K | 72.2% | 1,350 | Jul 20, 2026 | — | Form 4 |
| Herrmann Ken Director | Sell | 1,350 | $24.56 | $33.16K | 100% | 0 | Jul 20, 2026 | — | Form 4 |
| Herrmann Ken Director | Option exercise | 3,065 | $0.08 | $245.2 | New | 3,065 | Jul 17, 2026 | — | Form 4 |
| Herrmann Ken Director | Sell | 3,065 | $25.21 | $77.26K | 100% | 0 | Jul 17, 2026 | — | Form 4 |
| Ron-Bigger Shulamit COO | Option exercise | 50,000 | $3.66 | $183.00K | New | 50,000 | Jul 8, 2026 | — | Form 4 |
| Ron-Bigger Shulamit COO | Sell | 15,800 | $27.13 | $428.68K | 31.6% | 34,200 | Jul 8, 2026 | — | Form 4 |
| Ron-Bigger Shulamit COO | Sell | 30,000 | $27.94 | $838.14K | 87.7% | 4,200 | Jul 8, 2026 | — | Form 4 |
| Ron-Bigger Shulamit COO | Sell | 4,200 | $28.75 | $120.74K | 100% | 0 | Jul 8, 2026 | — | Form 4 |
| Czibere Akos Other | Option exercise | 50,000 | $4.95 | $247.50K | New | 50,000 | Jul 8, 2026 | — | Form 4 |
| Czibere Akos Other | Sell | 14,800 | $27.13 | $401.48K | 29.6% | 35,200 | Jul 8, 2026 | — | Form 4 |
| Czibere Akos Other | Sell | 30,829 | $27.95 | $861.74K | 87.6% | 4,371 | Jul 8, 2026 | — | Form 4 |
| Czibere Akos Other | Sell | 4,371 | $28.71 | $125.48K | 100% | 0 | Jul 8, 2026 | — | Form 4 |
| MPM BIOVENTURES 2018, L.P. Other | Converted | 1,577,119 | — | — | 20.8% | 9,147,287 | Jan 12, 2026 | — | Form 4 |
| MPM BIOVENTURES 2018, L.P. Other | Buy | 1,112,777 | $18.00 | $20.03M | 12.2% | 10,260,064 | Jan 12, 2026 | — | Form 4 |
| MPM BIOVENTURES 2018, L.P. Other | Converted | 5,914,197 | — | — | 357% | 7,570,168 | Jan 12, 2026 | — | Form 4 |
| MPM BIOVENTURES 2018, L.P. Other | Converted | 1,314,262 | — | — | 385% | 1,655,971 | Jan 12, 2026 | — | Form 4 |
| Vida Ventures II, LLC Other | Buy | 22,545 | $18.00 | $405.81K | 16.7% | 157,387 | Jan 12, 2026 | — | Form 4 |
| Vida Ventures II, LLC Other | Converted | 134,842 | — | — | New | 134,842 | Jan 12, 2026 | — | Form 4 |
| Vida Ventures II, LLC Other | Buy | 812,455 | $18.00 | $14.62M | 16.7% | 5,671,825 | Jan 12, 2026 | — | Form 4 |
| Vida Ventures II, LLC Other | Converted | 4,859,370 | — | — | New | 4,859,370 | Jan 12, 2026 | — | Form 4 |
| Segal Lloyd Mitchell Director | Converted | 19,631 | — | — | New | 19,631 | Jan 12, 2026 | — | Form 4 |
| Kim Helen Susan Director | Buy | 22,545 | $18.00 | $405.81K | 16.7% | 157,387 | Jan 12, 2026 | CCluster BuyFirst BuyDilution | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Buy (P) — Open-market or private purchase
- Sell (S) — Open-market or private sale
- Option exercise (M) — Exercise or conversion of an exempt derivative
- Converted (C) — Conversion of a derivative security into shares
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.